© John Wiley & Sons, Ltd.
Edited By: Francesco Bertoni
Impact Factor: 2.355
ISI Journal Citation Reports © Ranking: 2013: 38/68 (Hematology); 123/202 (Oncology)
Online ISSN: 1099-1069
1. AIMS AND SCOPE
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
- Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
- Diagnostic investigations, including imaging and laboratory assays
- Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
- Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
- Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
We work together with Wiley’s open access journal, Clinical Case Reports, to enable rapid publication of good quality case reports that we are unable to accept for publication in our journal. Authors of case reports rejected by our journal will be offered the option of having their case report, along with any related peer reviews, automatically transferred for consideration by the Clinical Case Reports editorial team. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. Clinical Case Reports will consider case reports from every clinical discipline and may include clinical images or clinical videos. Clinical Case Reports is an open access journal, and article publication fees apply. For more information please go to www.clinicalcasesjournal.com.
2. MANUSCRIPT SUBMISSION
All submissions should be made online at the Hematological Oncology ScholarOne Manuscripts (formerly known as Manuscript Central) site— http://mc.manuscriptcentral.com/hon . New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre.
3. MANUSCRIPT PREPARATION
Manuscripts must be written in English.
Text should be supplied in a format compatible with Microsoft Word for Windows (PC). Charts and tables are considered textual and should also be supplied in a format compatible with Word. All figures (illustrations, diagrams, photographs) should be supplied (uploaded) as separate tiff files in RGB or greyscale mode with no profile embedded and no layers. Figures must not be embedded in the Word document.
All illustrations must be supplied at the correct resolution:
- Black and white and colour photos - 300 dpi
- Graphs, drawings, etc - 800 dpi preferred; 600 dpi minimum
- Combinations of photos and drawings (black and white and colour) - 500 dpi
All manuscripts must be typed in 12pt font and in double space with margins of at least 2.5 cm.
The first page of the manuscript should contain the following information:
- the title of the paper
- a running head not exceeding 50 characters
- 2–6 article keywords
- names of authors
- names of the institutions at which the research was conducted
- name, address, telephone and fax number, and email address of corresponding author
- source(s) of support in the form of grants, equipment, drugs or all of these
- an accurate word count of the text from the start of the introduction to the end of the discussion
This should in general, but not necessarily, be divided into sections with the headings: Introduction, Methods, Results, Discussion, Conclusion.
Articles should not exceed 3000 words excluding references. Review articles and special features may exceed these limits by arrangement with the Editor-in-Chief. Succinct articles are likely to make a greater impact on readers than long ones and are more likely to be accepted for publication without delay.
Authors submitting papers should note that abstracts in prose form (not structured) of up to 300 words are required. The abstract should state the purposes of the study or investigation, the basic procedures, the main findings and the principal conclusions. It should emphasise new and important aspects of the study or observations. It should be understandable without reference to the rest of the paper and should contain no citation to other published work.
Tables and Figures
Tables and figures should not be inserted in the appropriate place in the text but should be included at the end of the paper, each on a separate page.
Tables and figures should be referred to in text as follows: Figure 1, Figure 2; Table 1, Table 2. Each table and/or figure must have a legend that explains its purpose without reference to the text.
Authors are themselves responsible for obtaining permission to reproduce previously published figures or tables.
Hematological Oncology employs the Vancouver reference style. References should be indicated in the text with Arabic numbers inside square brackets, e.g., , [1,2] or [1–3]. The full references should be listed numerically in order of appearance, and presented following the text of the manuscript. The Journal uses the following conventions for references:
- Going JJ, Moffat DF. Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J Pathol 2004; 203 :538–544.
- Watson F, Herrington CS. Blotting techniques: Methodology and Applications. In Molecular Biology in Histopathology , (2nd edn), Crocker J, Murray PG (eds). John Wiley & Sons Ltd: Chichester, 2003;1–15.
- Stevens A, Lowe J. Pathology (2nd edn). Mosby: London, 2000;224–226.
(Titles of periodicals should be abbreviated according to the style used in Index Medicus.)
4. REVIEW PROCESS
Manuscripts are assigned sequentially to Associate Editors . An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor’s comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors. A decision is made usually within six weeks of the receipt of the manuscript. The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.
A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.
Authors may provide the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief.
The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.
Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. The author must supply a full statement to the Editor-in-Chief about all submissions and previous reports that might be regarded as redundant or duplicate publication of the same or very similar work.
Conflict of Interest
Authors are responsible for disclosing all financial and personal relationships between themselves and others that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Investigators should disclose potential conflicts to study participants and should state in the manuscript whether they have done so. Authors should describe the role of the study sponsor(s), if any, in study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the report for publication. If the supporting source had no such involvement, the authors should so state.
When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or a national research council's guide for, or any national law on, the care and use of laboratory animals was followed. A statement describing explicitly the ethical background to the studies being reported should be included in all manuscripts in the Materials and Methods section. Ethics committee or institutional review board approval should be stated.
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. Identifying details should be omitted if they are not essential but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.
All persons designated as authors should qualify for authorship and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to published article. Authorship credit should be based only on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published. Conditions 1, 2 and 3 must all be met. Acquisition of funding, the collection of data or general supervision of the research group, by themselves, do not justify authorship. All others who contributed to the work who are not authors should be named in the Acknowledgements section.
Committee on Publication Ethics (COPE)
As a member of the Committee on Publication Ethics (COPE), adherence to these submission criteria is considered essential for publication in Hematological Oncology ; mandatory fields are included in the online submission process to ensure this. If, at a later stage in the submission process or even after publication, a manuscript or authors are found to have disregarded these criteria, it is the duty of the Editor-in-Chief to report this to COPE. COPE may recommend that action may be taken, including but not exclusive to, informing the authors' professional regulatory body and/or institution of such a dereliction.
The website for COPE may be accessed at: http://www.publicationethics.org.uk
6. ADDITIONAL INFORMATION ON ACCEPTANCE
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. The corresponding author MUST submit the CTA as it is a requirement for publication.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html..
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
Proofs of accepted articles will be sent to the author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimise the risk of the paper being held over to a later issue.
Note to NIH Grantees
Pursuant to NIH mandate, Wiley Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate
Free access to the final PDF offprint or your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.
To purchase reprints in smaller quantities, please visit http://www3.interscience.wiley.com/aboutus/ppv-articleselect.html. Restrictions apply to the use of reprints– if you have a specific query, please contact firstname.lastname@example.org. Corresponding authors are invited to inform their co-authors of the reprint options available.
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://onlinelibrary.wiley.com/onlineOpenOrder
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
EarlyView is Wiley's exclusive service presenting individual articles online as soon as they are ready before the release of the compiled print issue. EarlyView articles are complete, citable and are published in an average time of 6 weeks from acceptance.